Do you want to read an article? Please log in or register.
The forefront of ovarian cancer therapy: update on PARP inhibitors
Gynecologic Cancer
Related content
Gynecologic Cancer
Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials
Cancer Treat Rev.
Ruscito I, Bellati F, Ray-Coquard I, Mirza MR, du Bois A, Gasparri ML, Costanzi F, De Marco MP, Nuti M, Caserta D, Pignata S, Dorigo O, Sehouli J, Braicu EI
doi: 10.1016/j.ctrv.2020.102040.
RECOMMENDED
Gynecologic Cancer
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
J Clin Oncol.
Tew WP, Lacchetti C, Ellis A, Maxian K, Banerjee S, Bookman M, Jones MB, Lee JM, Lheureux S, Liu JF, Moore KN, Muller C, Rodriguez P, Walsh C, Westin SN, Kohn EC
doi: 10.1200/JCO.20.01924.
Genitourinary Cancer
Use of First-Line PARP Inhibitors in Ovarian Cancer
healthbook TIMES Oncology Hematology
Hasler-Strub U.
doi: 10.36000/hbT.OH.2019.02.006
RECOMMENDED
Gynecologic Cancer
Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status
Cancer Treat Rev.
Tomao F, Bardhi E, Di Pinto A, Sassu CM, Biagioli E, Petrella MC, Palaia I, Muzii L, Colombo N, Panici PB
doi: 10.1016/j.ctrv.2019.101909.
RECOMMENDED
Gynecologic Cancer
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
★ 2
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Ann Oncol.
Miller RE, Leary A, Scott CL, Serra V, Lord CJ, Bowtell D, Chang DK, Garsed DW, Jonkers J, Ledermann JA, Nik-Zainal S, Ray-Coquard I, Shah SP, Matias-Guiu X, Swisher EM, Yates LR
doi: 10.1016/j.annonc.2020.08.2102.
Immune-Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era
Clin Cancer Res.
Maio M, Hamid O, Larkin J, Covre A, Altomonte M, Calabrò L, Vardana SA, Robert C, Ibrahim R, Anichini A, Wolchok JD, Di Giacomo AM
doi: 10.1158/1078-0432.CCR-20-1657.
Breast Cancer
Recent Developments in Metastatic Breast Cancer
healthbook TIMES Oncology Hematology
Gynecologic Cancer
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Lancet Oncol.
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators
doi: 10.1016/
Gynecologic Cancer
Tumor-associated macrophage targeted therapeutics in ovarian cancer
Int J Cancer.
An Y, Yang Q
doi: 10.1002/ijc.33408.